Fig. 1.

Clinical course with hepatitis after BNT162b2 vaccination.

(A) Time course of ALT, AST, ALP, GGT and bilirubin levels after BNT162b2 vaccination in the patient. Arrows indicate the timepoint of BNT162b2 prime and boost vaccination. Arrowheads indicate timepoint of liver biopsy. Duration and dose of budesonide (9 mg/d) and prednisolone therapy (initially 50 mg/d) is shown in light blue and grey colorization. (B) Comparison of anti-spike S1 IgG antibody titers between patients and timepoint-matched vaccines who did not develop hepatitis. (C) Longitudinal analysis of anti-spike S1 IgG antibodies before and after the initiation of therapy. ALP, alanine phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; dpb, days post boost; GGT, gamma-glutamyltransferase.